Pharmaceutical

Allied is committed to developing cutting-edge technology that focuses on treating mental illness, specifically targeted at PTSD and other forms of mental trauma for Veterans and First Responders.

Pharma Development Model

Allied Corp. Strengthens IP and Pharma Strategy by Filing Provisional Patent for ALID-10 and ALID 11

On August 31, 2020, we announced the filing of a new United States provisional patent application entitled “Compositions and Methods for Modulating Endocannabinoid Systems Activity and Treating Mental Health Disorders”. The patent application covers Allied’s proprietary products, ALID-10 and ALID-11, as well as other novel cannabis derived compounds designed for superior pharmaceutical properties for treatment of PTSD and other mental disorders.

“The filing of this patent application supports our strategy of developing novel and differentiated cannabis derived pharmaceuticals for PTSD, our lead therapeutic indication”, said Calum Hughes, CEO of Allied. “We are continuing to build a solid patent portfolio to maximize the value of ALID-10 and ALID-11, which are currently in Phase 1 human clinical trials. Strengthening our patent portfolio is an important pillar in our pharmaceutical development strategy. After securing our Phase I clinical data and IMP number for commercialization, we intend to license this to a big pharma partner”.

“We are very excited to begin taking the strategic steps to developing and protecting our IP&PD strategy in the United States and around the world. Allied is committed to the development of a thoughtful and strategic Intellectual Property portfolio that is strengthened internationally by this filing.”
Jim Smeeding, VP Pharma Development
“We are very excited to begin taking the strategic steps to developing and protecting our IP&PD strategy in the United States and around the world. Allied is committed to the development of a thoughtful and strategic Intellectual Property portfolio that is strengthened internationally by this filing.”
Jim Smeeding, VP Pharma Development
“Currently, there are approximately 8 million people in the United States alone who suffer from symptoms related to PTSD. Although there are certain cognitive therapies that have proven to be helpful, there is no pharmaceutical drug that has an indication for this disease target. PTSD is a disorder that not only affects the person suffering, but his/her family and community as well. Through this patent filing, we have now taken the first step in our pharma development plan, as well as, protected our medical formulation that is focused on this disease target.”
Calum Hughes, CEO

Pre-clinical

  • Master Services Agreement with the University of Haifa, Israel via their wholly owned commercialization subsidiary: Carmel – Haifa University Economic Corporation Ltd. This world-class academic research center gives Allied access to a proprietary pre-clinical animal model that is owned by Carmel.
  • Allied announced the filing of a new United States provisional patent application entitled “Compositions and Methods for Modulating Endocannabinoid Systems Activity and Treating Mental Health Disorders”.
  • Intellectual property is owned by Allied Corp

Clinical

  • Late stage discussions with large Clinical Research Centres and Contract Research Organizations (CRO’s) for Clinical Trials
  • PHASE I clinical trial anticipated for Q3 2020
  • After completion of PHASE I, Allied intends to license to Big Pharma for commercialization

Sign up to our newsletter and get first access to the latest investor news, events, and other important information related to Allied Health.

Keep Informed